Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
446. |
ECCT/23/04/04 | AGREE Oral antenatal L-citrulline supplementation to reduce adverse pregnancy outcomes: a two-arm, randomized, placebo-controlled multi-site trial in Kenya |
Principal Investigator(s) 1. Hellen Barsosio Site(s) in Kenya 1. Ahero County Hospital (Kisumu county) 2. Alupe sub-county Hospital (Busia county) 3. Siaya County Referral Hospital (Siaya county) |
View |
447. |
ECCT/15/01/05 | In vivo efficacies of AL and DP Open label randomized study evaluating the in vivo efficacies of Artemether-lumefantrine and Dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in children under five years of age in western Kenya. |
Principal Investigator(s) 1. AAron Samuels 2. Simon Kariuki Site(s) in Kenya Siaya District Hospital |
View |
448. |
ECCT/20/10/02 | MALCOV Malaria as a risk factor for COVID-19 in western Kenya and Burkina Faso (MALCOV) |
Principal Investigator(s) 1. Simon Kariuki 2. Helen Barsosio Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOORTH), (Kisumu county) 2. Kisumu County Referral Hospital. (Kisumu county) 3. Alupe sub-County Hospital, (Busia county) 4. Bondo sub-County Hospital, (Siaya county) 5. Macalder (Nyatike) sub-County Hospital (Migori county) 6. Migori County Teaching and Referral Hospital; (Migori county) |
View |
449. |
ECCT/24/12/02 | IAVI C113 IAVI C113: A Phase 2b, double-blind, randomized, placebo-controlled study to evaluate the efficacy, safety and immunogenicity of a candidate tuberculosis (TB) vaccine, MTBVAC, against TB disease in interferon gamma release assay positive adolescents and adults aged 14-45 years, living in a TB endemic region. |
Principal Investigator(s) 1. Videlis Nduba 2. Tina Lucas Site(s) in Kenya 1. KEMRI,Centre for Respiratory Diseases Research (Nairobi City county) 2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county) |
View |
450. |
ECCT/16/04/01 | HVTN 703/HPTN 081 Protocol A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection HVTN 703/HPTN 081 A phase 2b study to evaluate the safety and efficacy of VRC01 broadly neutralizing monoclonal antibody in reducing acquisition of HIV-1 infection |
Principal Investigator(s) 1. Dr. Victor Akelo Akelo Site(s) in Kenya KISUMU CRS |
View |